Existing diabetes drug Victoza could be effective treatment for world’s obese
Pharmaceutical companies are racing to find a new form of obesity drug as patient numbers spiral and current products suffer from poor efficacy and reputation, according to new research from analyst firm Datamonitor Healthcare.
Leading the way is Danish insulin giant Novo Nordisk (NOV: N) with its diabetes drug Victoza (liraglutide) which is currently undergoing regulatory scrutiny in the USA and European Union. In its diabetes indication, Victoza generated first-quarter sales of 2.92 billion Danish kroner ($538 million) for the company. It is approved and marketed at lower doses of 1.2mg and 1.8mg once-daily.
Nearly 180 million people across France, Germany, Italy, Spain and the UK, as well as the USA, are classified as obese and this number is set to rise to just under 200 million by 2030. Numbers in the UK will reach 16 million by the end of the next decade.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze